EGFR and lung disorder: A case–control study revealed the main risk factors of CIP through prior lung disease, thoracic radiotherapy (RT), and combination treatment of ICIs or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), with odds ratios (OR): 2.86, 3.34, and 2.73, respectively.18